NextCure Inc., a leading clinical-stage biopharmaceutical firm, is making strides in the field of immunomedicine by developing advanced therapies to combat cancer and other immune-related diseases. With a focus on restoring normal immune function, the Maryland-based company is leading the charge to offer hope and support to patients in need. NextCure's impressive pipeline includes NC410, an immunomedicine built to block immune suppression mediated by LAIR-1, NC762, a monoclonal antibody that specially targets B7-H4, a protein expressed on multiple tumor types, and NC525, a monoclonal antibody designed to selectively bind to LAIR-1 to functionally kill AML blast cells and leukemic stem cells, while preserving normal blood cells, including hematopoietic stem cells. The firm's innovative approach to researching and developing treatments is underpinned by robust discovery and research programs, including an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. NextCure has a strategic license agreement with Yale University, and was established in 2015 with headquarters in Beltsville, Maryland.